Loading…
Sudeep Pharma (SUDEEPPHRM)₹1,210−0.14%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Sudeep Pharma reported sales of ₹197 Cr, up 20.7% from Sep 2025, and net profit of ₹51.93 Cr, up 10.6% year on year. For the year to Mar 2026, sales were ₹641 Cr and net profit ₹174 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 | 197 |
| Expenses | 84.71 | 75.70 | 98.64 | 80.68 | 107 | 112 | 119 | 103 | 123 |
| Operating Profit | 62.81 | 38.85 | 58.82 | 43.86 | 54.85 | 59.79 | 62.75 | 54.84 | 72.75 |
| OPM % | 43.0% | 34.0% | 37.0% | 34.9% | 34.0% | 35.0% | 34.0% | 35.0% | 37.0% |
| Other Income | 2.01 | 2.01 | 4.01 | 5.01 | 10.01 | 7.01 | 6.01 | 5.01 | 6.01 |
| Interest | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 | 1.01 | 2.01 | 2.01 | 3.01 |
| Depreciation | 3.01 | 3.01 | 3.01 | 3.01 | 4.01 | 4.01 | 4.01 | 4.01 | 5.01 |
| Profit before tax | 62.10 | 38.05 | 58.02 | 44.03 | 60.04 | 62.04 | 63.10 | 54.09 | 71.06 |
| Tax % | 21.0% | 24.0% | 24.0% | 29.1% | 21.0% | 23.1% | 23.0% | 25.0% | 27.0% |
| Net Profit | 48.93 | 28.99 | 43.97 | 30.98 | 46.96 | 47.93 | 48.98 | 40.94 | 51.93 |
| EPS (Rs) | 5.82 | 2.96 | 4.55 | 3.18 | 4.72 | 4.21 | 4.34 | 3.60 | 4.57 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 215 | 343 | 428 | 458 | 501 | 641 | 708 |
| Expenses | 97.61 | 170 | 275 | 337 | 275 | 309 | 417 | 456 |
| Operating Profit | 24.94 | 43.89 | 66.73 | 89.70 | 183 | 191 | 222 | 250 |
| OPM % | 20.9% | 20.0% | 20.0% | 20.9% | 40.0% | 38.0% | 35.0% | 35.3% |
| Other Income | 3.01 | 3.01 | 7.01 | 9.01 | 6.01 | 9.01 | 28.05 | 24.04 |
| Interest | 1.01 | 1.01 | 2.01 | 6.01 | 5.01 | 7.02 | 8.02 | 8.04 |
| Depreciation | 3.01 | 4.01 | 5.01 | 8.02 | 9.01 | 11.03 | 15.03 | 17.04 |
| Profit before tax | 25.03 | 43.02 | 69.05 | 86.15 | 175 | 183 | 228 | 250 |
| Tax % | 27.0% | 22.0% | 27.0% | 28.1% | 24.0% | 24.0% | 24.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 17.98 | 32.97 | 49.99 | 61.93 | 133 | 139 | 174 | 190 |
| EPS (Rs) | 2.16 | 3.98 | 5.98 | 7.44 | 15.89 | 14.30 | 15.35 | 16.72 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 9.96 | 10.96 |
| Reserves | 80.02 | 113 | 162 | 222 | 355 | 481 | 872 |
| Borrowings | 19.99 | 30.99 | 83.96 | 82.97 | 77.88 | 140 | 150 |
| Other Liabilities | 30.13 | 67.09 | 97.45 | 113 | 80.21 | 85.74 | 140 |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,173 |
| Fixed Assets | 60.23 | 68.30 | 138 | 159 | 181 | 190 | 338 |
| CWIP | 7.98 | 23.92 | 7.97 | 25.90 | 44.87 | 87.63 | 184 |
| Investments | 5.99 | 19.01 | 0.00 | 2.99 | 0.00 | 0.00 | 0.00 |
| Other Assets | 56.93 | 102 | 199 | 232 | 289 | 438 | 651 |
| Inventories | 9.99 | 16.99 | 36.95 | 70.91 | 66.92 | 129 | 216 |
| Trade receivables | 29.97 | 55.01 | 107 | 93.90 | 145 | 185 | 228 |
| Cash & equivalents | 3.99 | 11.98 | 21.01 | 9.99 | 13.99 | 51.98 | 115 |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,173 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 9.99 | 34.96 | −2.99 | 47.99 | 65.95 | 48.94 | 69.99 |
| Cash from investing activity | −21.96 | −39.91 | −37.91 | −49.89 | −48.92 | −78.80 | −326 |
| Cash from financing activity | 12.02 | 13.02 | 51.12 | −10.02 | −13.03 | 53.09 | 248 |
| Net cash flow | 0.00 | 7.97 | 9.98 | −10.96 | 3.99 | 22.92 | −9.98 |
| Capex | 8.99 | 11.98 | 73.99 | 46.94 | 51.92 | 63.91 | 118 |
| Free cash flow | 1.01 | 24.01 | −77.01 | 0.99 | 12.99 | −15.01 | −48.98 |
| CFO / OP % | 62.1% | 104.1% | 22.0% | 78.0% | 60.0% | 47.0% | 56.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory days | 76 | 78 | 103 | 141 | 146 | 308 | 355 |
| Days payable | 71 | 80 | 77 | 78 | 113 | 146 | 114 |
| Cash conversion cycle | 96 | 92 | 141 | 144 | 149 | 297 | 371 |
| Working capital days | 45 | 12 | 29 | 91 | 98 | 143 | 174 |
| ROCE % | — | 35.9% | 36.0% | 33.0% | 48.9% | 35.9% | 27.9% |
For the Sep 2026 quarter, Sudeep Pharma reported sales of ₹197 Cr, up 20.7% year on year and net profit of ₹51.93 Cr, up 10.6% year on year. The operating margin was 37.0%.
Sudeep Pharma's sales for the year to Mar 2026 were ₹641 Cr; over the last twelve months they were ₹708 Cr.
Net profit for the year to Mar 2026 was ₹174 Cr, and ₹190 Cr over the last twelve months. Earnings per share over the same trailing period were ₹16.72.
Sudeep Pharma reported borrowings of ₹150 Cr at Mar 2026, against cash and equivalents of ₹115 Cr.
Cash from operations was ₹69.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹48.98 Cr.